Joe Tucker, CEO of Enveric Biosciences, discusses the use of neuroplastogen therapies for the treatment of neuropsychiatric disorders, including depression, anxiety, and post-traumatic stress disorder. Enveric has developed the…
Read More
The psychedelic prodrug psilocybin has shown therapeutic benefits for the treatment of numerous psychiatric conditions. Despite positive clinical end points targeting depression and anxiety, concerns regarding the duration of the…
Read More
As we step into 2024, the biotechnology industry stands at a pivotal point, driven by rapid advancements in technology and shifting market dynamics. The past few years have been transformative,…
Read More
The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substances like psilocybin and MDMA to treat mental health conditions, this sector has…
Read More
Biotechnology company Enveric Biosciences has selected EB-003 as its lead drug candidate from its EVM301 series for difficult-to-treat mental health disorders. EB-003 was selected by the company based on data…
Read More
A conversation with Enveric Biosciences CEO Joseph Tucker, Ph.D. Two themes have arisen as of late in the clinical trials space, and both collide in this Q&A for an interesting…
Read More
The non-partisan Digital Politics Podcast with Karen Jagoda highlights the impact of new technologies on the campaign landscape, how expectations of voters are changing, role of online fundraising, digital and…
In this episode of The Mindfulness Experience Podcast, host Keith Fiveson interviews Dr. Joseph Tucker, the CEO and Director of Enveric Biosciences. Enveric Biosciences is a biotechnology company that is…
Read More
Enveric Biosciences has received a Notice of Allowance (NoA) from the United States Patent and Trademark Office (USPTO) for a patent application involving EB-373, the company’s new chemical entity (NCE)…
Read More
Expands its intellectual property portfolio with composition of matter claims governing lead clinical candidate, EB-373, a psilocin prodrug being developed for the treatment of depression and anxiety disorders. CAMBRIDGE, Mass.…
Read More
